secwatch.observer — SEC 8-K summary
======================================

Issuer:     Equillium, Inc. (EQ)
CIK:        0001746466
Form:       8-K
Filed at:   2024-04-01T23:59:59+00:00
Accession:  0001193125-24-082709
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Equillium reports positive Phase 1b itolizumab data in lupus nephritis
----------------------------------------------------------------------

- Topline data: 16 patients; baseline mean UPCR 4.9 g/g → ~73% reduction; overall response rate 81.3% (CR+PR).
- Complete response in 37.5%, partial response in 43.8%; ORR comparable to Phase 3 AURORA1 voclosporin study.
- Safety: mostly mild/moderate TEAEs (lymphopenia, peripheral edema); no treatment-related serious AEs; >80% steroid taper.
- Data triggers Ono's option to acquire itolizumab; decision expected H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746466/000119312524082709/0001193125-24-082709-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746466/000119312524082709/d819425d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-082709

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer